Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Reexamination Certificate
2007-04-17
2007-04-17
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
C424S085100, C424S184100, C424S277100, C424S278100, C424S620000, C424S629000, C424S649000, C600S001000, C514S002600, C514S008100, C514S012200, C514S021800, C514S023000, C514S025000, C514S027000, C514S028000, C514S029000, C514S031000, C514S034000, C514S045000, C514S049000, C514S050000, C514S090000, C514S109000, C514S110000, C514S171000, C514S183000, C514S184000, C514S185000, C514S249000, C514S251000, C514S274000, C514S283000, C514S444000, C514S449000, C514S492000, C514S504000, C514S559000, C514S575000, C514S
Reexamination Certificate
active
10698625
ABSTRACT:
The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
REFERENCES:
patent: 132275 (1872-10-01), Gettings
patent: 232807 (1880-10-01), Dennett
patent: 3700498 (1972-10-01), Kanazawa et al.
patent: 4497780 (1985-02-01), Barin et al.
patent: 4599305 (1986-07-01), Witte et al.
patent: 5759837 (1998-06-01), Kuhajda et al.
patent: 6720011 (2004-04-01), Zhang
patent: 6733792 (2004-05-01), Lu
patent: 6770304 (2004-08-01), Warrell, Jr. et al.
patent: 1061908 (1992-06-01), None
patent: 1079391 (1993-12-01), None
patent: 1081104 (1994-01-01), None
patent: 1119113 (1996-03-01), None
patent: 1121807 (1996-05-01), None
patent: 1122700 (1996-05-01), None
patent: 1131037 (1996-09-01), None
patent: 1133725 (1996-10-01), None
patent: 51-88620 (1976-03-01), None
patent: WO 94/02108 (1994-02-01), None
patent: WO 95/01789 (1995-01-01), None
patent: WO 95/22336 (1995-08-01), None
Medline abstract, accession No. 83131994 (1990).
Medline abstract, accession No. 77108084 (1990).
“Arsen (III)—Sulfid As2S2”, Gmelin's Arsenic, 8th. Edition, 17:422-433, 1952.
“Diarsendisfulid As2S2”, Gmelin's Arsenic, 8th. Edition, 17:412-422, 1952.
“Goodman & Gilman's The pharmacological basis of therapeutics”, 9thEdition, McGraw-Hill, Health Professions Division, pp. 1659-1662, (date unknown).
“Inorganic Arsenic Compounds Other Than Arsine Health and Safety Guide, Health and Safety Guide No. 70”, WHO, Geneva, 1992.
“Xionghuang Realgar”, Chinese Pharmacopia (1), Guangdong Science and Technology Publishing House, China, pp. 298-299, 1995.
Akao et al. “Arsenic Induces Apoptosis B-cell Leukemic Cell Lines In Vitro: Activation of Caspases and Down-regulation of Bcl-2 Protein”, British J of Hematology, 102. 1055-1060, 1998.
Andre et al., “The PML and PML/RAR.alpha Domains: from autoimmunity to molecular oncology and from retionic acid to arsenic”, Experimental Cell Research, 229:253-260, 1996.
Arsenic, Environmental Health Criteria 18, Geneva: WHO, 1981.
Chemical Abstract, 63-Pharmaceuticals 11:317, #111:219272j and 111:219276p, 1987-1991.
Chen et al., “In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic Leukemia: As2O3induces NB4cell apoptosis with down regulation of Bcl-2 expression and modulation of PML-RAR.alpha/PML proteins”, Blood 88(3): 1052-1061, 1996.
Chen et al., “Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia (APL):I. As2O3Exerts Dose-Dependent Dual Effects on APL Cells” Blood 89(9):3345-3353, 1997.
Chung et al., “Influence for Carcinoma Cell and Lymphatic cell of Acetyl Arsonate”, Yakhak Hoeji 40(5):599-607, 1996.
Cutler et al., Article IV, American Journal of the Medical Sciences, pp. 74-84, (date unknown).
Cuzick et al., “Medicinal arsenic and internal malignancies”, Br. J. Cancer, 45:904-911, 1982.
De The, “L'oxyde d'arsenic: aprės l'acide retinoique, un nouveau traitement cible de la leucemie aigue promyelocytaire” medicine/sciences; 13: 867-71, 1997.
Dictionary of Inorganic Compounds, vol. 1, Ac-C10, IC-000667-IC-000671, (date unknown).
Flamigni et al., “Effect of Sodium Arsenite on the Induction and Turnover of Ornithine Decarboxylase Activity in Erythroleukemia Cells” Cell Biochemistry and Function 7:213-217, 1989.
Fluka, 1995/96 Catalog: 152-153.
Forkner et al., “Arsenic as a therapeutic agent in chronic myelogenous leukemia”, Journ. A.M.A. 97(1)-3-5, 1931.
Germolec et al., “Arsenic induces over expression of growth factors in human keratinocytes”, Toxicology and Applied Pharmacology, 141:308-318, 1996.
Huang et al., 1995, “The Clinical Study of QINGDAI Tablet For Treating Acute Promyelocytic Leukemia” China Magazine of Hematology, 16(1):26.
Ishinishi N. et al., “Study on Chronic Toxicity of Arsenic Trioxide in Rats with Special Reference to the Liver Damages”Fukuok Acta Medicine, 71:27, 1980.
Kasper et al., “Hepatic Angiosarcoma and bronchioloalveolar carcinoma induced by Fowler's solution”, JAMA 252(24):3407-3408, 1984.
Kerkvliet et al., Immunotoxicology Studies of Sodium Arsenate-effects of Exposure on Tumor Growth and Cell-mediated Tumor Immunity, J. Environmental Pathology and Toxicology 4:65-79, 1980.
Konig et al., “Comparative Activity of Melarsoprol and Arsenic Trioxide in Chronic B-Cell Leukemia Lines”, Blood 90(2):562-570, 1997.
Kwong et al., “Delicious Poison: Arsenic Trioxide for the treatment of Leukemia”, Blood 89:3487-8, 1997.
Lee et al., “Induction of Gene Amplification by Arsenic”, Science, 241: 79-81, 1988.
Li et al. “Traditional Chinese and Western Medicine in the Treatment of 27 Patients with Malignant Lymphoma”, Chinese J. Oncology, 10:61-62, 1988.
Lu et al., “Effective treatment of AML-M3 (APL) and their remission maintenance wit Realgar: A pilot clinical and laboratory study on 38 patients”, Blood 90(10 Suppl. 1 part 1):416A, #1849, 1997.
Lu et al., “Study of Realgar in the treatment of acute promyelocytic Leukemia (APL)- a pilot clinical and laboratory study on 38 patients”, China-Korea Medical Conference '97 1997.
Mervis, “Ancient remedy performs new tricks”, Science 273: 578, 1996.
Monfardini et al., “Survival in chronic myelogenous leukemia: influence of treatment and extent of disease at diagnosis”, Cancer, 31:492-501, 1973.
Neubauer, “Arsenic Cancer: a review”, Arsenical Cancer, Arsenic Committee of the Medical Research Council, pp. 192-251, 1947.
Pershagen et al., “On the pulmonary tumorigenicity of arsenic trisulfide and calcium arsenate in hamsters”, Cancer Letter, 27:99-104, 1985.
Pories et al., “Trace Elements that Act to Inhibit Neoplastic Growth”, Annals New York Academy of Sciences, 199: pp. 265-273, 1972.
Qi and Bi, “Method for removing As2O3from Realgar”, Chung Yao Tung Pao, 8(5):21-22, 1983.
Reichl et al., “Effect of Arsenic on Cellular Metabolism after Single or Repeated Injection in Guinea Pigs”, Arch. Toxicol., Suppl. 13. p. 363-65, 1989.
Remington's Pharmaceutical Sciences, Mach Publishing Co., Easton, PA, p. 1570-80, 1990.
Schenk, Handbook of Preparative Inorganic Chemistry, 1:603, G. Brauer, Ed., Academic press, New York, 2ndEd. 1963.
Shen et al., “Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic Leukemia (APL):II. Clinical efficacy and pharmacokinetics in relapsed patients”, Blood 89(9):3354-3360, 1997.
Shibuya, “Studies on Experimental Arsenious Acid Poising”, Tokyo Jikeikai Ika Daigaku Zasshi 86(4):653, 1971.
Soignet et al., “Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide”, J of Medicine 339:19, 1998.
Stephens et al. “The therapeutic effect of solution of potassium arsenite in chronic myelogenous leukemia” Ann. Inern. Assoc 9:1488-1502, 1936.
Suehiro Shimotsuura et al., “Studies on the Antineoplasmic Actions of As2O3”, Shikwa Gakuho 86:1237-1253, 1986.
Sun et al., “Ai Ling #1 and Traditional Chinese Medicine in the Treatment of 32 patients with Acute Promyelocytic Leukemia”, Chinese of J. Traditional Chinese and Western Medicine 1(3), 1992.
Treleaven et al., “Arsenic and Ayurveda&#x
Ellison Ralph M.
Marmelstein Fred H.
Cephalon, Inc.
Pak John
Polarx Biopharmaceuticals, Inc.
LandOfFree
Compositions and methods for the treatment of primary and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment of primary and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of primary and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3770168